Am Fam Physician. 2010 Apr 1;81(7):838-840.
Original Article: Pharmacologic Management of Hypertension in Patients with Diabetes
Issue Date: December 1, 2008
Available at: http://www.aafp.org/afp/2008/1201/p1277.html
to the editor: I read with interest the article on hypertension in patients with diabetes mellitus. The authors did not mention the effect of beta blockers on lipid profile. Patients with diabetes and hypertension may have metabolic syndrome, which is a common disorder. Long-term administration of beta blockers in such patients could increase triglyceride levels and decrease high-density lipoprotein levels,1 which are also features of metabolic syndrome. This might complicate lipid status and require further unnecessary antihyperlipidemic agents.
Author disclosure: Nothing to disclose.
1. Bangalore S, Messerli FH. Beta-blockers as fourth-line therapy for hypertension: stay the course. Int J Clin Pract. 2008;62(11):1643–1646.
in reply: We thank Dr. Kittisupamongkol for his commentary. Administration of beta blockers has been associated with alterations in the lipoprotein profile, namely an increase in triglycerides and a decrease in high-density lipoprotein (HDL) cholesterol. However, the effects do not appear to be significant enough to recommend against the use of beta blockers in patients with diabetes mellitus.
A meta-analysis that examined 315 trials of beta-blocker antihypertensive therapy concluded that beta blockers, on average, were associated with a 30 mg per dL (0.34 mmol per L) increase in triglycer-ides and a 4 mg per dL (0.10 mmol per L) decrease in HDL cholesterol.1 In a subset of trials in which the duration of beta-blocker therapy was greater than one year, there was no significant change in triglycerides, suggesting that some effects on the lipid profile may be transient. A Veterans Affairs Cooperative Study observed similar results.2 After one year of maintenance therapy with atenolol (Tenormin), triglyceride levels did not differ significantly from patients randomized to receive hydrochlorothiazide, captopril (Capoten), clonidine (Catapres), diltiazem (Cardizem), prazosin (Minipress), or placebo.2 The 2.9 mg per dL (0.08 mmol per L) reduction in HDL cholesterol levels observed in patients receiving atenolol was not statistically significant compared with the other treatment groups.2
One proposed theory for the lipoprotein effects of beta blockers is that suppression of beta-adrenergic activity leads to unopposed alpha-adrenergic stimulation. In turn, alpha-adrenergic stimulation leads to a decrease in peripheral lipoprotein lipase activity and a subsequent reduction in catabolism of very low-density lipoprotein and triglycerides.3 Antagonism of peripheral beta-adrenergic receptors is much less with the cardioselective beta blockers, and lower doses of these agents have negligible effects on lipoprotein parameters. Thus, for patients who need a beta blocker, a cardioselective agent is preferred.3,4
It is important to remember that hypertension in patients with diabetes is often difficult to manage, and most patients require multiple medications to reach the blood pressure target of less than 130/80 mm Hg.4,5 Many times a beta blocker will need to be included as part of the antihypertensive regimen to achieve adequate blood pressure control. Current evidence-based guidelines for the management of hypertension in patients with diabetes do not mention concerns about lipoprotein changes with beta-blocker therapy, and continue to recommend beta blockers as an alternative treatment for hypertension in patients with diabetes.4,5 For this reason, we chose not to mention the lipoprotein effects of beta blockers in the article. However, we did address the more critical concern of the potential for beta blockers to blunt the signs of hypoglycemia and worsen glucose intolerance.
Controlling blood pressure is integral to reducing cardiovascular risk in patients with diabetes.4,5 Therefore, if it is a choice between adding a beta blocker to gain adequate control of blood pressure or avoiding beta blocker use to minimize the possibility of slight changes in the lipoproteins, the choice should be to use the beta blocker. The benefits of blood pressure control in patients with diabetes outweigh the relatively minor risk of alterations in the lipid profile with beta blocker use.
Author disclosure: Nothing to disclose.
REFERENCESshow all references
1. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122(2):133–141....
2. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159(6):551–558.
3. Weir MR, Moser M. Diuretics and beta-blockers: Is there a risk for dyslipidemia? Am Heart J. 2000;139(1 pt 1):174–184.
4. Chobanian AV, Bakris GL, Black HR, et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197] JAMA. 2003;289(19):2560–2572.
5. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;(33 suppl 1):S11–S61.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions